Nothing Special   »   [go: up one dir, main page]
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2011 1
2013 1
2016 1
2018 1
2019 1
2020 5
2022 3
2023 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.
Herrero Rivera D, Vacas CG, Kovandzic LM, Vázquez JP, Alonso LA, González BM, Aragón VC, Grande E, Caro RL, Virizuela Echaburu JA, Rodríguez Moreno JF, Etxebarria AA, Rodríguez-Antona C, Durán I. Herrero Rivera D, et al. Among authors: vazquez jp. Pharmacogenomics. 2022 Jul;23(11):627-638. doi: 10.2217/pgs-2022-0023. Epub 2022 Jul 26. Pharmacogenomics. 2022. PMID: 35880554
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
Di Pietro O, Alencar N, Esteban G, Viayna E, Szałaj N, Vázquez J, Juárez-Jiménez J, Sola I, Pérez B, Solé M, Unzeta M, Muñoz-Torrero D, Luque FJ. Di Pietro O, et al. Among authors: vazquez j. Bioorg Med Chem. 2016 Oct 15;24(20):4835-4854. doi: 10.1016/j.bmc.2016.06.045. Epub 2016 Jun 28. Bioorg Med Chem. 2016. PMID: 27396685
23 results